JÁ García-Sáenz

A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN

Santiago González Vázquez, J. Grau, JÁ García-Sáenz et al. · Journal of Clinical Oncology · 2009 · 21 citations

Pharmacotherapy, Cancer Chemotherapy, Radiation Medicine +17

Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study.

Marc Pujalte‐Martin, Sibylle Loibl, G von Minckwitz et al. · Cancer Research · 2012 · 18 citations

Breast Oncology, Lea Study, Adjuvant Chemotherapy +18

Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy

F-C Bidard, Stefan Michiels, Volkmar Mueller et al. · Cancer Research · 2017 · 13 citations

Surgical Oncology, Breast Oncology, Individual Patient Data +19

Abstract OT2-01-06: Phase III study of <u>p</u>albociclib (PD-0332991) in combination with <u>e</u>ndocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with <u>r</u>esistance to <u>a</u>romatase inhibitors. <i>“The PEARL study”</i> (GEICAM/2013-02)

M. Martín, Zsuzsanna Kahán, Eva Carrasco et al. · Cancer Research · 2017 · 10 citations

Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

Miguel Martín, CH Barrios, Laura Torrecillas et al. · Cancer Research · 2019 · 10 citations

Surgical Oncology, Breast Oncology, Adjuvant Capecitabine +18